Published in J Virol on December 01, 2000
Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase? J Virol (2004) 2.35
Recent progress in herpes simplex virus immunobiology and vaccine research. Clin Microbiol Rev (2003) 2.06
Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci U S A (2007) 1.82
mRNA decay during herpes simplex virus (HSV) infections: protein-protein interactions involving the HSV virion host shutoff protein and translation factors eIF4H and eIF4A. J Virol (2005) 1.56
Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. J Virol (2002) 1.39
The virion host shutoff protein of herpes simplex virus 1 blocks the replication-independent activation of NF-κB in dendritic cells in the absence of type I interferon signaling. J Virol (2011) 1.26
Herpes simplex virus virion host shutoff attenuates establishment of the antiviral state. J Virol (2008) 1.18
The virion host shut-off (vhs) protein blocks a TLR-independent pathway of herpes simplex virus type 1 recognition in human and mouse dendritic cells. PLoS One (2010) 1.15
Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection. J Virol (2002) 1.04
A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol (2011) 1.02
Small interfering RNAs that deplete the cellular translation factor eIF4H impede mRNA degradation by the virion host shutoff protein of herpes simplex virus. J Virol (2008) 1.01
Disruption of the U(L)41 gene in the herpes simplex virus 2 dl5-29 mutant increases its immunogenicity and protective capacity in a murine model of genital herpes. Virology (2007) 1.00
Activation and evasion of innate antiviral immunity by herpes simplex virus. Viruses (2009) 0.94
Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine. Future Virol (2012) 0.92
Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J Virol (2011) 0.87
Mice with mutations in Fas and Fas ligand demonstrate increased herpetic stromal keratitis following corneal infection with HSV-1. J Immunol (2011) 0.86
Herpes simplex virus infection stabilizes cellular IEX-1 mRNA. J Virol (2005) 0.85
Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine (2009) 0.83
Construction and properties of a herpes simplex virus 2 dl5-29 vaccine candidate strain encoding an HSV-1 virion host shutoff protein. Vaccine (2010) 0.81
B7 costimulation molecules encoded by replication-defective, vhs-deficient HSV-1 improve vaccine-induced protection against corneal disease. PLoS One (2011) 0.81
A proautophagic antiviral role for the cellular prion protein identified by infection with a herpes simplex virus 1 ICP34.5 mutant. J Virol (2013) 0.81
Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. Curr Pharm Des (2007) 0.76
Impaired Fas-Fas Ligand Interactions Result in Greater Recurrent Herpetic Stromal Keratitis in Mice. J Immunol Res (2015) 0.75
Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res (1985) 10.76
The isolation and properties of a variant of Herpes simplex producing multinucleated giant cells in monolayer cultures in the presence of antibody. Am J Hyg (1959) 9.21
Herpes simplex virus turns off the TAP to evade host immunity. Nature (1995) 5.93
Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. J Virol (1988) 5.11
Genetic analysis of temperature-sensitive mutants which define the gene for the major herpes simplex virus type 1 DNA-binding protein. J Virol (1983) 3.98
Herpes simplex virus-infected cells contain a function(s) that destabilizes both host and viral mRNAs. Proc Natl Acad Sci U S A (1987) 3.75
Herpes simplex virus virion host shutoff function. J Virol (1988) 3.22
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. J Gen Virol (1987) 3.16
Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science (1998) 3.15
Quantitative polymerase chain reaction analysis of herpes simplex virus DNA in ganglia of mice infected with replication-incompetent mutants. J Virol (1990) 3.05
Definition of a series of stages in the association of two herpesviral proteins with the cell nucleus. J Virol (1982) 2.99
Control of mRNA stability by the virion host shutoff function of herpes simplex virus. J Virol (1989) 2.65
Effects of herpes simplex virus on mRNA stability. J Virol (1987) 2.53
Genetic evidence for multiple nuclear functions of the herpes simplex virus ICP8 DNA-binding protein. J Virol (1989) 2.35
Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. J Virol (1995) 2.26
Early and delayed shut-off of host protein synthesis in cells infected with herpes simplex virus. J Gen Virol (1982) 2.22
The herpes simplex virus vhs protein induces endoribonucleolytic cleavage of target RNAs in cell extracts. J Virol (1999) 1.96
The virion host shutoff protein of herpes simplex virus type 1: messenger ribonucleolytic activity in vitro. J Virol (1996) 1.95
In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts. J Gen Virol (1993) 1.93
Human herpes simplex virus (HSV)-specific CD8+ CTL clones recognize HSV-2-infected fibroblasts after treatment with IFN-gamma or when virion host shutoff functions are disabled. J Immunol (1996) 1.88
The herpes simplex virus virion host shutoff function. J Virol (1989) 1.86
Influence of mucosal and parenteral immunization with a replication-defective mutant of HSV-2 on immune responses and protection from genital challenge. Virology (1998) 1.86
Herpes simplex virus non-structural proteins. III. Function of the major DNA-binding protein. J Gen Virol (1983) 1.79
Characterization of two conformational forms of the major DNA-binding protein encoded by herpes simplex virus 1. J Virol (1982) 1.75
Herpes simplex virus-induced stromal keratitis: role of T-lymphocyte subsets in immunopathology. J Virol (1989) 1.72
Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology (1989) 1.59
Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection. Proc Natl Acad Sci U S A (1999) 1.54
HLA class I molecules are not transported to the cell surface in cells infected with herpes simplex virus types 1 and 2. J Immunol (1994) 1.53
Accumulation of viral transcripts and DNA during establishment of latency by herpes simplex virus. J Virol (1998) 1.52
Immunization with replication-defective mutants of herpes simplex virus type 1: sites of immune intervention in pathogenesis of challenge virus infection. J Virol (1994) 1.42
Tolerance and immunity in mice infected with herpes simplex virus: simultaneous induction of protective immunity and tolerance to delayed-type hypersensitivity. Immunology (1981) 1.36
Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells. J Virol (1987) 1.35
Herpes simplex virus type 2 ICP47 inhibits human TAP but not mouse TAP. J Virol (1998) 1.33
Mechanisms of immunization with a replication-defective mutant of herpes simplex virus 1. Virology (1996) 1.26
Transfer of UL41, the gene controlling virion-associated host cell shutoff, between different strains of herpes simplex virus. J Gen Virol (1990) 1.25
Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease. Virology (1997) 1.23
Mutational analysis of the virion host shutoff gene (UL41) of herpes simplex virus (HSV): characterization of HSV type 1 (HSV-1)/HSV-2 chimeras. J Virol (1997) 1.22
Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice. J Virol (2000) 1.17
Concurrent regeneration of T lymphocytes and susceptibility to HSV-1 corneal stromal disease. Curr Eye Res (1991) 1.14
Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine (1998) 1.14
Role of Lyt-1 positive immune T cells in recovery from herpes simplex virus infection in mice. Microbiol Immunol (1982) 1.11
Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted. J Virol (1994) 1.11
Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1. Virology (1997) 1.08
Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice. Vaccine (1998) 1.04
Th1-associated immune responses to beta-galactosidase expressed by a replication-defective herpes simplex virus. J Immunol (1996) 0.93
Role of epidermal Langerhans cells in resistance to herpes simplex virus infection. Arch Virol (1986) 0.91
Susceptibility of +/+, +/nu and nu/nu BALB/c mice to ocular herpes simplex virus infection. Ophthalmic Res (1992) 0.84
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Differences in antigen presentation to MHC class I-and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med (1986) 5.11
Genetic diversity among Botulinum Neurotoxin-producing clostridial strains. J Bacteriol (2006) 4.75
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science (1986) 4.40
Hospital and physician volume or specialization and outcomes in cancer treatment: importance in quality of cancer care. J Clin Oncol (2000) 4.01
The three-dimensional structure of canine parvovirus and its functional implications. Science (1991) 3.87
Nucleocapsid and glycoprotein organization in an enveloped virus. Cell (1995) 3.66
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. J Clin Oncol (2000) 3.38
Thymidine kinase-negative herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not reactivate. Proc Natl Acad Sci U S A (1989) 3.26
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
Telling the truth about terminal cancer. JAMA (1998) 3.07
Antiviral agent blocks breathing of the common cold virus. Proc Natl Acad Sci U S A (1998) 2.71
Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg (1996) 2.68
Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev (1987) 2.64
Crystal structure of human rhinovirus serotype 1A (HRV1A). J Mol Biol (1989) 2.49
Fibroblasts as sentinel cells. Synthesis of chemokines and regulation of inflammation. Am J Pathol (1997) 2.47
Association of heart rate variability with occupational and environmental exposure to particulate air pollution. Circulation (2001) 2.46
Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46
Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol (1992) 2.42
Control of cytomegalovirus retinitis using sustained release of intraocular ganciclovir. Arch Ophthalmol (1993) 2.39
A retrospective cohort study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1988) 2.38
Structural analysis of a series of antiviral agents complexed with human rhinovirus 14. Proc Natl Acad Sci U S A (1988) 2.30
Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis. J Virol (1995) 2.26
A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology (1989) 2.10
Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg (1993) 2.08
Effective strategy for prenatal prediction of Duchenne and Becker muscular dystrophy. Lancet (1987) 2.08
A case-control study of lung cancer and diesel exhaust exposure in railroad workers. Am Rev Respir Dis (1987) 2.07
Encephalopathy and fatty degeneratiof on the viscera in northeastern Thailand. Clinical syndrome and epidemiology. Pediatrics (1971) 2.00
The role of autolysins during vegetative growth of Bacillus subtilis 168. Microbiology (1998) 1.97
In vivo characterization of site-directed mutations in the promoter of the herpes simplex virus type 1 latency-associated transcripts. J Gen Virol (1993) 1.93
Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virol (1989) 1.92
Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res (2000) 1.86
Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel (2010) 1.80
Physical and biological properties of dengue-2 virus and associated antigens. J Virol (1970) 1.75
Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2000) 1.71
Measuring standards of care for early breast cancer in an insured population. J Clin Oncol (1997) 1.71
Class I major histocompatibility complex-restricted cytolytic T lymphocytes recognize a limited number of sites on the influenza hemagglutinin. Proc Natl Acad Sci U S A (1989) 1.68
Recognition of pre-processed endogenous antigen by class I but not class II MHC-restricted T cells. Nature (1989) 1.67
Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med (1991) 1.67
Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol (2005) 1.62
Pulmonary function in firefighters: acute changes in ventilatory capacity and their correlates. Br J Ind Med (1979) 1.61
The efficacy of specimen radiography in evaluating the surgical margins of impalpable breast carcinoma. AJR Am J Roentgenol (1994) 1.54
Safety, accuracy, and diagnostic yield of needle localization biopsy of the breast performed using local anesthesia. J Am Coll Surg (1994) 1.49
Modeling particle exposure in U.S. trucking terminals. Environ Sci Technol (2006) 1.49
Dose coefficients for the embryo and foetus following intakes of radionuclides by the mother. J Radiol Prot (2002) 1.47
Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones. J Exp Med (1985) 1.46
The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse. J Clin Oncol (1992) 1.45
2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol (2000) 1.43
Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods. Diabetologia (2006) 1.42
The use of viscoelastic substances in the drainage of postoperative suprachoroidal hemorrhage. Ophthalmic Surg (1989) 1.40
Deletions of fetal and adult muscle cDNA in Duchenne and Becker muscular dystrophy patients. EMBO J (1987) 1.40
Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect Immun (1998) 1.39
Health effects of gasoline exposure. II. Mortality patterns of distribution workers in the United States. Environ Health Perspect (1993) 1.39
Fungal virus capsids, cytoplasmic compartments for the replication of double-stranded RNA, formed as icosahedral shells of asymmetric Gag dimers. J Mol Biol (1994) 1.39
Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol (1999) 1.39
Pulmonary effects of exposures in silicon carbide manufacturing. Br J Ind Med (1984) 1.39
Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing quadrant. Int J Radiat Oncol Biol Phys (1993) 1.38
Corneal traction suture in trabeculectomy. Ophthalmic Surg (1991) 1.37
Estimation of the diesel exhaust exposures of railroad workers: I. Current exposures. Am J Ind Med (1988) 1.35
Tumor biology of infiltrating lobular carcinoma. Implications for management. Ann Surg (1995) 1.35
Human lung tryptase. Purification and characterization. J Biol Chem (1984) 1.33
Human orbital fibroblasts are activated through CD40 to induce proinflammatory cytokine production. Am J Physiol (1998) 1.32
Herpes simplex virus type 1 corneal infection results in periocular disease by zosteriform spread. J Virol (2001) 1.31
Clinical significance of histopathologic patterns of cardiac amyloidosis. Mayo Clin Proc (1984) 1.30
Targeted modification of the apolipoprotein B gene results in hypobetalipoproteinemia and developmental abnormalities in mice. Proc Natl Acad Sci U S A (1993) 1.28
Variation in staging and treatment of local and regional breast cancer in the elderly. Breast Cancer Res Treat (1996) 1.27
Factors that determine the treatment for local and regional prostate cancer. Med Care (1996) 1.27
Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol (2000) 1.27
A prospective study of hepatic imaging in the detection of metastatic disease. Ann Surg (1982) 1.26
Conformational variability of a picornavirus capsid: pH-dependent structural changes of Mengo virus related to its host receptor attachment site and disassembly. Virology (1990) 1.26
A poxvirus protein that binds to and inactivates IL-18, and inhibits NK cell response. J Immunol (2000) 1.25
Respiratory exposures associated with silicon carbide production: estimation of cumulative exposures for an epidemiological study. Br J Ind Med (1984) 1.23
Antibody-mediated neutralization of human rhinovirus 14 explored by means of cryoelectron microscopy and X-ray crystallography of virus-Fab complexes. J Virol (1998) 1.23
Molecular cloning and characterization of the human and mouse UDP-glucose dehydrogenase genes. J Biol Chem (1998) 1.22
Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol (1996) 1.21
Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy-Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol (2000) 1.21
Estimation of the diesel exhaust exposures of railroad workers: II. National and historical exposures. Am J Ind Med (1988) 1.21
Doses to organs and tissues from radon and its decay products. J Radiol Prot (2002) 1.20
Anatomical route of invasion and protective mucosal immunity in Trypanosoma cruzi conjunctival infection. Infect Immun (2006) 1.20
Structure determination of an Fab fragment that neutralizes human rhinovirus 14 and analysis of the Fab-virus complex. J Mol Biol (1994) 1.19
Airborne arsenic exposure and excretion of methylated arsenic compounds. Environ Health Perspect (1977) 1.19
Structure-activity relationships of arylalkyl isothiocyanates for the inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone metabolism and the modulation of xenobiotic-metabolizing enzymes in rats and mice. Carcinogenesis (1993) 1.18
CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J Immunol (1998) 1.18
Herpes simplex virus virion host shutoff (vhs) activity alters periocular disease in mice. J Virol (2000) 1.17
Viral replication is required for induction of ocular immunopathology by herpes simplex virus. J Virol (1996) 1.17
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points. J Clin Oncol (1998) 1.17
Analysis of conserved domains of UL41 of herpes simplex virus type 1 in virion host shutoff and pathogenesis. J Virol (1996) 1.17
Rabbit macrophage interferons. II. Some physicochemical properties and estimations of molecular weights. J Exp Med (1967) 1.16
A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer (1998) 1.16
Parsing eye-tracking data of variable quality to provide accurate fixation duration estimates in infants and adults. Behav Res Methods (2013) 1.15
Mortality studies of machining fluid exposure in the automobile industry I: A standardized mortality ratio analysis. Am J Ind Med (1992) 1.15
A locus for cerebral cavernous malformations maps to chromosome 7q in two families. Genomics (1995) 1.15
Protection from primary infection and establishment of latency by vaccination with a herpes simplex virus type 1 recombinant deficient in the virion host shutoff (vhs) function. Vaccine (1998) 1.14
Congenital anaemia after transplacental B19 parvovirus infection. Lancet (1994) 1.13